

# Anthony J Rothschild

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2827085/publications.pdf>

Version: 2024-02-01

174  
papers

7,140  
citations

57758

44  
h-index

66911

78  
g-index

179  
all docs

179  
docs citations

179  
times ranked

5726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II report. <i>Psychological Medicine</i> , 2022, 52, 3957-3963.	4.5	2
2	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.3	4
3	Psychopharmacology. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 1-2.	1.4	0
4	Characteristics of Working-Age Adults With Schizophrenia Newly Admitted to Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1227-1235.e3.	2.5	1
5	Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. <i>Psychiatry Research</i> , 2022, 314, 114648.	3.3	3
6	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 76-85.	0.8	0
7	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.3	8
8	Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 196-199.	1.4	5
9	The Pitfalls of Psychotropic Polypharmacy. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 227-232.	1.4	7
10	Why Is There No Food and Drug Administrationâ€‘Approved Medication for Major Depression With Psychotic Features?. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 359-361.	1.4	4
11	An Introduction and My Vision for JCP. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 1-2.	1.4	0
12	Effects of Preexisting Psychotropic Medication Use on a Cohort of Patients with Ischemic Stroke Outcome. <i>Stroke Research and Treatment</i> , 2020, 2020, 1-8.	0.8	0
13	Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 29, 645-654.	1.2	2
14	Changes in depressive symptoms and cognitive impairment in older long-stay nursing home residents in the USA: a latent transition analysis. <i>Aging and Mental Health</i> , 2020, 25, 1-10.	2.8	5
15	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.2	13
16	Structural brain networks in remitted psychotic depression. <i>Neuropsychopharmacology</i> , 2020, 45, 1223-1231.	5.4	17
17	Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features. <i>JAMA Psychiatry</i> , 2020, 77, 674.	11.0	76
18	Depression symptoms and cognitive impairment in older nursing home residents in the <sc>USA</sc>: A latent class analysis. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 769-778.	2.7	17

#	ARTICLE	IF	CITATIONS
19	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.3	18
20	Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 622.	7.4	53
21	O21. Resting-State Functional Connectivity, Cortical Gaba and Allopregnanolone in Postpartum Depression: A Functional Magnetic Imaging and Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, S114.	1.3	1
22	177. Effects of Antipsychotic Medication on Brain Structure: Data From a Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2019, 85, S73.	1.3	0
23	Trial of SAGE-217 in Patients with Major Depressive Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 903-911.	27.0	156
24	178. Brain Network Biomarkers of Remitted Psychotic Depression. <i>Biological Psychiatry</i> , 2019, 85, S73-S74.	1.3	0
25	Advances in the Treatment of Psychotic Depression. <i>Current Treatment Options in Psychiatry</i> , 2019, 6, 64-74.	1.9	1
26	Health-related quality of life in remitted psychotic depression. <i>Journal of Affective Disorders</i> , 2019, 256, 373-379.	4.1	3
27	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care. The reality of treatment resistant-based therapies. <i>Journal of Psychiatric Research</i> , 2019, 114, 211-213.	3.1	1
28	HEALTH-RELATED QUALITY OF LIFE IN REMITTED PSYCHOTIC DEPRESSION. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, S177-S178.	1.2	0
29	<p>Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 457-468.	2.2	28
30	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	45
31	176. Sustaining Remission of Psychotic Depression: The Stop-PD II Study. <i>Biological Psychiatry</i> , 2019, 85, S72-S73.	1.3	0
32	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
33	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	197
34	Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study. <i>Neuropsychopharmacology</i> , 2019, 44, 546-554.	5.4	57
35	Psychotic depression and suicide. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 364-365.	4.5	5
36	White matter integrity in medication-free women with peripartum depression: a tract-based spatial statistics study. <i>Neuropsychopharmacology</i> , 2018, 43, 1573-1580.	5.4	27

#	ARTICLE	IF	CITATIONS
37	Continuation Treatment of Remitted Psychotic Depression: The STOP-PD Study. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S86-S87.	1.2	0
38	Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis. <i>American Journal of Men's Health</i> , 2018, 12, 5-13.	1.6	25
39	Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. <i>EBioMedicine</i> , 2018, 36, 446-453.	6.1	10
40	Stabilization treatment of remitted psychotic depression: the STOP-PD study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 267-273.	4.5	6
41	O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2018, 83, S127-S128.	1.3	0
42	Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 672-679.	1.2	13
43	949. Replicated Aberrant Default Mode Resting State Functional Connectivity in Patients with Remitted Psychotic Depression. <i>Biological Psychiatry</i> , 2017, 81, S384.	1.3	0
44	Depression and cognitive impairment among newly admitted nursing home residents in the USA. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1172-1181.	2.7	29
45	Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. <i>Lancet Psychiatry</i> , 2017, 4, 839-849.	7.4	382
46	Vitamin D supplementation in bipolar depression: A double blind placebo controlled trial. <i>Journal of Psychiatric Research</i> , 2017, 95, 48-53.	3.1	47
47	943. White Matter Integrity in Medication-Free Women with Peripartum Depression: Diffusion Tensor Imaging Study Using Tract-Based Spatial Statistics. <i>Biological Psychiatry</i> , 2017, 81, S381-S382.	1.3	0
48	69. Neuroactive Steroids and GABA in Peripartum Depression. <i>Biological Psychiatry</i> , 2017, 81, S28-S29.	1.3	0
49	The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1149-1154.	2.2	9
50	Benzodiazepines Do Not Cause Suicide or Suicide Attempts. <i>primary care companion for CNS disorders</i> , 2017, 19, .	0.6	4
51	Peripartum neuroactive steroid and $\hat{1}^3$ -aminobutyric acid profiles in women at-risk for postpartum depression. <i>Psychoneuroendocrinology</i> , 2016, 70, 98-107.	2.7	79
52	The Association of Baseline Suicidality with Treatment Outcome in Psychotic Depression. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, S103-S104.	1.2	0
53	Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. <i>Archives of Women's Mental Health</i> , 2016, 19, 769-778.	2.6	10
54	Does psychosis increase the risk of suicide in patients with major depression? A systematic review. <i>Journal of Affective Disorders</i> , 2016, 198, 23-31.	4.1	61

#	ARTICLE	IF	CITATIONS
55	Treatment for Major Depression With Psychotic Features (Psychotic Depression). Focus (American Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	1
56	Cortisol response to the Trier Social Stress Test in pregnant women at risk for postpartum depression. Archives of Women's Mental Health, 2016, 19, 789-797.	2.6	14
57	SSRI&antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP&PD study. Human Psychopharmacology, 2016, 31, 252-255.	1.5	9
58	Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). Journal of Affective Disorders, 2016, 190, 111-114.	4.1	14
59	Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. Journal of Women's Health, 2016, 25, 464-472.	3.3	9
60	Rating scales measuring the severity of psychotic depression. Acta Psychiatrica Scandinavica, 2015, 132, 335-344.	4.5	17
61	The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clinical Pharmacokinetics, 2015, 54, 1161-1168.	3.5	14
62	Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2015, 23, 1270-1275.	1.2	10
63	The Relationships Between Vascular Risk, Cognition and Outcome in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2015, 23, S102-S103.	1.2	0
64	Symptom severity of bipolar disorder during the menopausal transition. International Journal of Bipolar Disorders, 2015, 3, 35.	2.2	28
65	The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. Journal of Affective Disorders, 2015, 188, 270-277.	4.1	29
66	Clinical and psychometric validation of the psychotic depression assessment scale. Journal of Affective Disorders, 2015, 173, 261-268.	4.1	24
67	A Blood Test for Depression?. Journal of Clinical Psychiatry, 2015, 76, e218-e219.	2.2	3
68	Impaired Insight Into Delusions Predicts Treatment Outcome During a Randomized Controlled Trial for Psychotic Depression (STOP-PD Study). Journal of Clinical Psychiatry, 2015, 76, 427-433.	2.2	10
69	Vagus Nerve Stimulation and Food Intake. Journal of Diabetes Science and Technology, 2014, 8, 590-595.	2.2	26
70	The implications of the National Institute of Mental Health Research Domain Criteria for researchers and clinicians. Acta Psychiatrica Scandinavica, 2014, 130, 409-414.	4.5	4
71	Measuring psychotic depression. Acta Psychiatrica Scandinavica, 2014, 129, 211-220.	4.5	35
72	Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. Journal of Affective Disorders, 2014, 156, 119-125.	4.1	50

#	ARTICLE	IF	CITATIONS
73	Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. <i>Journal of Affective Disorders</i> , 2014, 160, 68-73.	4.1	29
74	Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. <i>Comprehensive Psychiatry</i> , 2014, 55, 1069-1076.	3.1	4
75	The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 1-10.	3.1	55
76	Effect of Sertraline on Risk of Falling in Older Adults with Psychotic Depression on Olanzapine: Results of a Randomized Placebo-Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 332-336.	1.2	13
77	Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 62-68.	2.2	31
78	Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD <sup>1</sup> <sup>2</sup> . <i>BMC Psychiatry</i> , 2013, 13, 38.	2.6	27
79	The treatment of psychotic depression: Is there consensus among guidelines and psychiatrists?. <i>Journal of Affective Disorders</i> , 2013, 145, 214-220.	4.1	48
80	GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: A preliminary study. <i>Journal of Psychiatric Research</i> , 2013, 47, 816-828.	3.1	114
81	Challenges in the Treatment of Major Depressive Disorder With Psychotic Features. <i>Schizophrenia Bulletin</i> , 2013, 39, 787-796.	4.3	81
82	The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 391-397.	1.4	9
83	Persistent delusional theme over 13 episodes of psychotic depression. <i>Acta Neuropsychiatrica</i> , 2013, 25, 370-373.	2.1	9
84	Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 266-273.	1.0	19
85	Antidepressant Augmentation Using the <i>N</i> -Methyl-D-Aspartate Antagonist Memantine. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 966-973.	2.2	67
86	A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD). <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1003-1009.	2.2	16
87	Considerations on the ICD-11 Classification of Psychotic Depression. <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 135-144.	8.8	37
88	Manic episode after total abdominal hysterectomy with bilateral salpingo-oophorectomy. <i>Menopause</i> , 2012, 19, 476-478.	2.0	2
89	Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. <i>Psychiatry Research</i> , 2012, 197, 221-226.	3.3	14
90	Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. <i>European Neuropsychopharmacology</i> , 2012, 22, 858-866.	0.7	46

#	ARTICLE	IF	CITATIONS
91	Rethinking the classification of mixed affective episodes in ICD-11. <i>Journal of Affective Disorders</i> , 2012, 138, 170-172.	4.1	9
92	Progression of female reproductive stages associated with bipolar illness exacerbation. <i>Bipolar Disorders</i> , 2012, 14, 515-526.	1.9	23
93	Relationships Between Multiple Sclerosis and Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 198-200.	1.8	39
94	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 96-103.	3.1	39
95	Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2011, 45, 896-901.	3.1	17
96	Psychosocial outcomes in patients with recurrent major depressive disorder during 2years of maintenance treatment with venlafaxine extended release. <i>Journal of Affective Disorders</i> , 2010, 126, 420-429.	4.1	34
97	Effect of Age on the Frequency of Anxiety Disorders in Major Depression With Psychotic Features. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 404-412.	1.2	35
98	Correlation between patient and clinician assessments of depression severity in the PREVENT study. <i>Psychiatry Research</i> , 2010, 177, 177-183.	3.3	40
99	Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?. <i>Journal of Affective Disorders</i> , 2009, 112, 250-255.	4.1	7
100	Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. <i>Journal of Affective Disorders</i> , 2009, 117, 18-23.	4.1	31
101	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. <i>Archives of General Psychiatry</i> , 2009, 66, 838.	12.3	188
102	Treating Depression and Psychosis. <i>Medical Psychiatry</i> , 2009, , 234-247.	0.2	0
103	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. <i>Psychopharmacology Bulletin</i> , 2009, 42, 5-20.	0.0	4
104	Correlates of Suicidality Among Patients with Psychotic Depression. <i>Suicide and Life-Threatening Behavior</i> , 2008, 38, 403-414.	1.9	35
105	The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity. <i>Comprehensive Psychiatry</i> , 2008, 49, 508-513.	3.1	12
106	Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. <i>International Clinical Psychopharmacology</i> , 2008, 23, 130-137.	1.7	15
107	Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1293-1296.	2.2	68
108	Psychiatric outcomes following medical and surgical abortion. <i>Human Reproduction</i> , 2007, 22, 878-884.	0.9	26

#	ARTICLE	IF	CITATIONS
109	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	1.3	39
110	Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 194-200.	2.2	40
111	Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1014-1023.	2.2	53
112	The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1246-1256.	2.2	93
113	A Delusion Assessment Scale for Psychotic Major Depression: Reliability, Validity, and Utility. <i>Biological Psychiatry</i> , 2006, 60, 1336-1342.	1.3	35
114	Olanzapine and haloperidol in first episode psychosis: Two-year data. <i>Schizophrenia Research</i> , 2006, 86, 234-243.	2.0	112
115	A Review of Postpartum Psychosis. <i>Journal of Women's Health</i> , 2006, 15, 352-368.	3.3	345
116	Placebo Response in Psychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1615.	2.2	2
117	Conflict-of-Interest Charge. <i>American Journal of Psychiatry</i> , 2004, 161, 1721-a-1722.	7.2	1
118	Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 385-392.	5.4	268
119	A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 365-373.	1.4	128
120	Challenges in the treatment of depression with psychotic features. <i>Biological Psychiatry</i> , 2003, 53, 680-690.	1.3	89
121	How Long Should Patients With Psychotic Depression Stay on the Antipsychotic Medication?. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 390-396.	2.2	31
122	An open label trial of C-1073 (mifepristone) for psychotic major depression*. <i>Biological Psychiatry</i> , 2002, 52, 386-392.	1.3	302
123	A Dynamic Algorithm for the Treatment of Psychotic Major Depression. <i>Psychiatric Annals</i> , 2002, 32, 681-691.	0.1	2
124	BENZODIAZEPINE RESPONSE. <i>American Journal of Nursing</i> , 2001, 101, 13.	0.4	0
125	Neuropsychological Deficits in Psychotic Versus Nonpsychotic Major Depression and No Mental Illness. <i>American Journal of Psychiatry</i> , 2000, 157, 1095-1100.	7.2	192
126	New directions in the treatment of antidepressant-induced sexual dysfunction. <i>Clinical Therapeutics</i> , 2000, 22, A42-A61.	2.5	37



#	ARTICLE	IF	CITATIONS
127	Comparison of the Frequency of Behavioral Disinhibition on Alprazolam, Clonazepam, or No Benzodiazepine in Hospitalized Psychiatric Patients. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 7-11.	1.4	37
128	Clinical Predictors of Acute Response With Quetiapine in Psychotic Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 185-189.	2.2	87
129	Sexual side effects of antidepressants. <i>Journal of Clinical Psychiatry</i> , 2000, 61 Suppl 11, 28-36.	2.2	23
130	Treatment of Antidepressant-Induced Sexual Dysfunction. <i>Hospital Practice (1995)</i> , 1999, 34, 89-96.	1.0	12
131	Selective Serotonin Reuptake Inhibitors and Delusional Depression. <i>American Journal of Psychiatry</i> , 1999, 156, 977a-978.	7.2	19
132	Olanzapine Response in Psychotic Depression. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 116-118.	2.2	73
133	Reply to "Can Long-Term Antidepressant Use Be Depressogenic?". <i>Journal of Clinical Psychiatry</i> , 1999, 60, 263-264.	2.2	0
134	McLean Hospital Depression Research Facility: early-onset phobic disorders and adult-onset major depression. <i>British Journal of Psychiatry</i> , 1998, 173, 29-34.	2.8	47
135	Loss of Antidepressant Efficacy During Maintenance Therapy. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 279-288.	2.2	122
136	Psychiatrists' responses to failure of maintenance therapy with antidepressants. <i>Psychiatric Services</i> , 1997, 48, 835-837.	2.0	22
137	Basal ganglia choline levels in depression and response to fluoxetine treatment: An in vivo proton magnetic resonance spectroscopy study. <i>Biological Psychiatry</i> , 1997, 41, 837-843.	1.3	107
138	MANAGEMENT OF PSYCHOTIC, TREATMENT-RESISTANT DEPRESSION. <i>Psychiatric Clinics of North America</i> , 1996, 19, 237-252.	1.3	37
139	Dr. Rothschild Replies. <i>American Journal of Psychiatry</i> , 1996, 153, 1371-1371.	7.2	0
140	On Psychotic Major Depression. <i>American Journal of Psychiatry</i> , 1996, 153, 847-847.	7.2	0
141	The diagnosis and treatment of late-life depression. <i>Journal of Clinical Psychiatry</i> , 1996, 57 Suppl 5, 5-11.	2.2	7
142	The Role of Dopamine in Psychotic Depression. <i>Clinical Neuropharmacology</i> , 1995, 18, S66-S73.	0.7	12
143	Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. <i>American Journal of Psychiatry</i> , 1995, 152, 1514-1516.	7.2	138
144	Advances in the management of depression: Implications for the obstetrician/gynecologist. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 659-666.	1.3	5

#	ARTICLE	IF	CITATIONS
145	Triazolam and disinhibition. <i>Lancet</i> , The, 1993, 341, 186.	13.7	5
146	Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. <i>Biological Psychiatry</i> , 1993, 34, 392-400.	1.3	35
147	Dr. Schatzberg and Dr. Rothschild Reply. <i>American Journal of Psychiatry</i> , 1993, 150, 1131-1131.	7.2	0
148	The Dexamethasone Suppression Test in Psychiatric Disorders. <i>Psychiatric Annals</i> , 1993, 23, 662-670.	0.1	9
149	Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. <i>Journal of Clinical Psychiatry</i> , 1993, 54, 338-42.	2.2	62
150	Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. <i>American Journal of Psychiatry</i> , 1992, 149, 733-745.	7.2	286
151	Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. <i>Journal of Clinical Psychiatry</i> , 1991, 52, 491-3.	2.2	92
152	Depression Secondary to Anxiety: Findings from the McLean Hospital Depression Research Facility. <i>Psychiatric Clinics of North America</i> , 1990, 13, 633-649.	1.3	22
153	Relationships between brain ct scan findings and cortisol in psychotic and nonpsychotic depressed patients. <i>Biological Psychiatry</i> , 1989, 26, 565-575.	1.3	91
154	The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 462-471.	3.8	40
155	Biology of Depression. <i>Medical Clinics of North America</i> , 1988, 72, 765-790.	2.5	20
156	Psychotic and nonpsychotic depressions: I. comparisons of plasma catecholamines and cortisol measures. <i>Psychiatry Research</i> , 1987, 20, 143-153.	3.3	56
157	Psychotic and nonpsychotic depressions: II. platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms. <i>Psychiatry Research</i> , 1987, 20, 155-164.	3.3	19
158	Delusional depression, family history, and DST response: A pilot study. <i>Biological Psychiatry</i> , 1986, 21, 1239-1246.	1.3	19
159	Mania After Withdrawal of Isocarboxazid. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 340-342.	1.4	18
160	Mania After Withdrawal of Isocarboxazid. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 340-342.	1.4	6
161	Toward a Biochemical Classification of Depressive Disorders IX. <i>British Journal of Psychiatry</i> , 1985, 146, 633-637.	2.8	15
162	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. <i>Life Sciences</i> , 1985, 36, 2491-2501.	4.3	100

#	ARTICLE	IF	CITATIONS
163	A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research, 1985, 19, 57-64.	3.1	232
164	Abnormal Results of Dexamethasone Suppression Tests in Nondepressed Patients With Diabetes Mellitus. Archives of General Psychiatry, 1984, 41, 1086.	12.3	88
165	Dexamethasone increases plasma free dopamine in man. Journal of Psychiatric Research, 1984, 18, 217-223.	3.1	68
166	The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. American Journal of Psychiatry, 1984, 141, 1550-1555.	7.2	54
167	The dexamethasone suppression test: identification of subtypes of depression. American Journal of Psychiatry, 1983, 140, 88-91.	7.2	146
168	Platelet MAO activity and the dexamethasone suppression test in depressed patients. American Journal of Psychiatry, 1983, 140, 1231-1233.	7.2	25
169	Fluctuating postdexamethasone cortisol levels in a patient with melancholia. American Journal of Psychiatry, 1982, 139, 129-130.	7.2	13
170	The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients. British Journal of Psychiatry, 1982, 141, 471-474.	2.8	72
171	Gas-phase pyrolysis of phenyltrimethylsilyldiazomethane. Intramolecular chemistry of phenyltrimethylsilylcarbene. Journal of the American Chemical Society, 1977, 99, 6995-6999.	13.7	26
172	Alleged intermediacy of a silacyclopropane in the pyrolysis of phenyltrimethylsilyldiazomethane. Journal of the American Chemical Society, 1975, 97, 657-658.	13.7	14
173	Neuroendocrinology of Mood Disorders. , 0, , 757-776.		0
174	Psychosis in Major Depression. , 0, , 156-194.		1